Country Level Incidence of Alzheimer Disease and Related Dementias is Associated with Increased Omega6 PUFA Consumption

- 3
- 4
- 5 Timothy H. Ciesielski^{*a}, Giuseppe Tosto^b, Razaq O. Durodoye^a, Farid Rajabali^c, Rufus O. Akinyemi^d,
- 6 Goldie S. Byrd^e, William S. Bush^{a,f}, Brian W. Kunkle^c, Christiane Reitz, Jeffery M. Vance^c, Margaret A.
- 7 Pericak-Vance^d, Jonathan L. Haines^{a,f}, and Scott M. Williams^{a,f}
- 8
- 9
- a Department of Population and Quantitative Health Sciences, Case Western Reserve University
- 11 School of Medicine, 10900 Euclid Ave. Cleveland, OH 44106
- 12 b Taub Institute for Research on Alzheimer Disease and the Aging Brain,
- 13 Department of Neurology, Columbia University College of Physicians and Surgeons, 630 West 168th
- 14 Street New York, NY 10032
- 15 c John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine
- 16 1501 NW 10th Ave. Biomedical Research Building, Miami, FL 33136
- 17 d Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training,
- 18 College of Medicine, University of Ibadan, P.M.B 5017 G.P.O Ibadan, Oyo State, Nigeria.
- 19 e Maya Angelou Center for Health Equity, Wake Forest University School of Medicine, 525 Vine
- 20 Street Suite #150, 1st Floor, Winston-Salem, NC 27101
- 21 f Cleveland Institute for Computational Biology, Case Western Reserve University, 2-530 Wolstein
- 22 Research Building, 2103 Cornell Road, Cleveland, OH
- 23

^{*} Corresponding Author:

- 25 Timothy H. Ciesielski Sc.D. M.D. M.P.H
- 26 Research Scientist, Department of Population and Quantitative Health Sciences
- 27 Case Western Reserve University School of Medicine
- 28 2210 Circle Drive, Robbins Building, Office E260, Cleveland, Ohio 44106
- 29

31

32 Abstract

33

- 34 **INTRODUCTION:** Clinical and genetic studies have implicated lipid dysfunction in Alzheimer Disease
- 35 (AD) pathogenesis. However, lipid consumption at the individual-level does not vary greatly within
- 36 most cohorts, and multiple lipids are rarely measured in any one study.
- 37
- 38 **METHODS:** Mean country-level lipid intakes were compared to Age-Standardized Alzheimer-
- 39 Disease-Incidence-Rates(ASAIR) in 183 countries across all inhabited continents. Penalized spline
- 40 regression and multivariable-adjusted linear regression, including a lag between intake and incidence,
- 41 were used to assess the relationships between five lipid intakes and ASAIR. Validation was
- 42 conducted using longitudinal within-country changes between 1990 and 2019.
- 43
- 44 **RESULTS:** Omega6 Polyunsaturated-Fatty-Acid(PUFA) intake exhibited a positive linear relationship
- 45 with ASAIR(multivariable-adjusted model: β =2.44; 95%CI: 1.70, 3.19; p=1.38x10⁻⁹). ASAIR also
- increased with saturated-fat, trans-fat, and dietary-cholesterol up to a threshold. The association
- 47 between Omega6-PUFA and ASAIR was confirmed using longitudinal intake changes.

- DISCUSSION: Decreasing Omega6-PUFA consumption on the country-level may have substantial
 benefits in reducing the country-level burden of AD.
- 51

52 Introduction

53

Convergent evidence from genetics, neuropathology, laboratory experiments, and epidemiology 54 indicates that lipids play a central role in the development of Alzheimer Disease (AD).^{1–9} However, the 55 relative importance of different lipids remains unclear, and individual-level epidemiologic studies are 56 often not well suited to address this guestion. Large cohort studies rarely have precise dietary 57 information on specific lipid intakes over decades, and even where these data are available, the lipid 58 intakes among individuals do not typically vary enough within a study population to discern patterns of 59 association. Additionally, multiple categories of lipids are not usually available in one dataset, so their 60 relative associations cannot be compared. Lastly, the potential for nonlinear relationships is rarely 61 considered. These caveats often lead to equivocal conclusions upon meta-analysis.¹⁰ However, 62 each of these issues is addressable with ecological analyses¹¹ on the country-level. Mean intake 63 levels for several lipid categories have now been measured with precision and they vary substantially 64 among nations.^{12,13} The range and density of these data should allow for: 1) resolution of associations 65 with AD incidence, and 2) the use of free-knot penalized spline regression¹⁴ to assess for nonlinear 66 relationships. Together these factors provide strong impetus for conducting ecological analyses on 67 the country-level that can characterize the relationship between large-scale lipid intake variations and 68 AD. 69

70

Here we obtained country-level data on five lipid intakes^{12,13}, and compared them to age-standardized Alzheimer Disease Incidence rates (ASAIR)¹⁵ using free-knot penalized spline regression and linear regression. We then attempted to validate our findings using longitudinal analyses that compared changes in country-level lipid intakes over 30 years to changes in ASAIR. These analyses do not

- rs seek to make inferences about individual level intakes and the risk of Alzheimer Disease for
- ⁷⁶ individuals. Thus, the ecological fallacy is not a relevant concern as both the exposure and the
- outcome are on the country-level. Country-level dietary data is the most appropriate data for studying
- country-level incidence rates and country-level interventions.
- 79
- 80
- 81 Results
- 82
- The mean ASAIR among the 183 countries was: 91.6 new cases per 100,000 per year with a
- standard deviation of 11.7 (Table 1). Mean country-level Omega 6 PUFA, saturated fat, and trans-fat
- intakes were 5.1%, 11.6%, and 1.1% of total energy intake, respectively, and the mean intakes for
 cholesterol and Omega3 PUFA were 323 and 249 mg/day, respectively.
- 87

88 Cross-sectional Analyses with a Lag

Bivariate (unadjusted) free-knot penalized spline regression analyses revealed a linear relationship 89 between country-level ASAIR and both Omega6 PUFA and Omega3 PUFA (Figure 1: A and B), but 90 non-linearity was detected for the remaining three lipids: saturated fat, trans-fat, and cholesterol 91 intake (Figure 1: C, D, and E). ASAIR increased with saturated fat up to ~10% of total energy intake, 92 and with trans-fat up to ~1.5% total energy intake. ASAIR also increased with dietary cholesterol 93 intake up to ~250 mg/day. Below these thresholds the relationships appeared linear, while above 94 these thresholds data was sparse. Thus, the slopes in the high intake regions of the exposure 95 distribution could not be estimated with confidence, although the plots generally showed slopes near 96 zero (Figure 1). 97

A multivariable linear regression model adjusted for all other lipids and country development level 99 (per capita GNI), revealed a positive association between Omega6 PUFA and ASAIR (Table 2: β = 100 2.44; 95%CI: 1.70, 3.19; p=1.38x10⁻⁹). For Omega3 PUFA there was a subtle negative trend, but the 101 relationship was not significant (β = -0.004; 95%CI: -0.010, 0.001; p=1.11x10⁻¹). Because the 102 remaining lipids were modeled with nonlinear splines, it was not appropriate to estimate a single 103 slope across the full exposure distribution for these lipids. However, as noted above, the remaining 104 lipid-ASAIR relationships appeared linear below lipid-specific thresholds. Thus, for the three 105 remaining lipids, we stratified by that lipid's specific threshold, and reran the multivariable model using 106 a linear term for that lipid. This allowed us to estimate slopes (Bs) within the linear regions of the 107 relationship. Below the threshold of 10% of total energy intake, we found a significant association 108 between saturated fat and ASAIR ($\beta = 2.67$: 95%CI: 1.23, 4.11; p=5.71x10⁻⁴). This relationship was 109 not evidence above the threshold ($\beta = 0.04$; 95%CI: -0.44, 0.53; p=8.62x10⁻¹). Similarly, trans-fat 110 intake was significantly associated with ASAIR below the threshold of 1.5% total energy (β = 7.35; 111 95%CI: 0.79, 13.90; p=2.96x10⁻²), but not above the threshold ($\beta = 0.70$; 95%CI: -1.89, 3.29; 112 p=6.03x10⁻¹). Finally, the relationship between cholesterol intake and ASAIR was significant below 113 the threshold of 250 mg/day ($\beta = 0.15$; 95%CI: 0.07, 0.23; p=5.98x10⁻⁴), but not above it ($\beta = 0.02$; 114 95%CI: -0.03, 0.07; p=3.61x10⁻¹). 115

116

117 Longitudinal Analyses

The longitudinal within-country changes in lipid intakes between 1990 and 2010 were small (Table 3), but the unadjusted regression model validated the association between Omega6-PUFA and ASAIR (Table 4; β = 0.0341; 95%CI: 0.0154, 0.0529; p=4.70x10⁻⁴). Unadjusted regression models for the other lipids yielded findings that were generally consistent with the cross-sectional findings, but none of the associations reached significance (Table 4). The longitudinal relationship between Omega6-

- PUFA and ASAIR remained significant upon multivariable adjustment (Table 4; β = 0.0375; 95%CI: 0.0164, 0.0586; p=6.50x10⁻⁴).
- 125
- 126
- 127 Discussion
- 128

We observed a multivariable-adjusted positive linear association between mean country-level intake 129 of Omega6 PUFA in 2010 and ASAIR in 2019. This association was then validated with a second 130 multivariable adjusted model using longitudinal data. Specifically, we found that the percent change 131 in the country-level Omega6 intake from 1990 to 2010 was positively associated with the percent 132 change ASAIR between 1990 and 2019. These findings need further validation and trials to establish 133 if the relationship is causal. However, the validation of this pattern in longitudinal data is among the 134 strongest corroborations that can be made in non-experimental data. We adjusted for all other lipids 135 to reduce the risk of bias. With a sample size of 183 countries, we found strong associations in 136 discovery and in longitudinal validation. These are exceptionally small p-values for an epidemiologic 137 study with this sample size. Our findings remain significant even under the most conservative 138 adjustment for multiple testing (considering both discovery and confirmatory regressions as 18 139 separate tests the Bonferroni adjusted threshold for α =0.05 would be p<2.8x10⁻³) 140

141

The association between Omega6 PUFA and Alzheimer Disease is consistent with prior literature in individual level human studies and animal experiments^{8,16–20}. While other studies have reported an inverse association between Omega3 PUFA and AD^{8,21}, here we only observed a non-significant trend in this direction. Omega3 and Omega6 PUFA share an endogenous processing pathway²² involving fatty acid desaturases (FADS) and elongases of very long chain fatty acids (ELOVL). Interestingly, the gene clusters that produce these enzymes are both implicated in AD ^{16,23}. Thus, our

findings are consistent with the hypothesis that the inflammatory endpoints of Omega6 processing
(e.g. Arachidonic Acid) are more important than the Omega-3 physiology for increasing the risk of
Alzheimer disease.

151

The magnitude of the initial association with Omega6 ($\beta = 2.44$: 95%CI: 1.70, 3.19; p=1.38x10⁻⁹) 152 indicates that a one standard deviation decrease (-1.9% as a percent of total daily energy intake) 153 could reduce ASAIR by 4.6 new cases of Alzheimer disease per 100.000 per year (2.44*1.9). For the 154 US, which reported an ASAIR of 110 new cases per 100,000 in 2019, a 2 standard deviation 155 decrease in mean Omega6 PUFA intake would amount to 8.4% reduction in new cases annually 156 ([110-9.2]/110 = 91.6%). In absolute numbers this translates into ~28,140 fewer new cases each year 157 (8.4*[335.000.000/100.000]). We did not evaluate Alzheimer Disease prevalence in this study 158 because prevalence is affected by survival time, which can involve factors that are not relevant to 159 disease etiology. However, if all other factors were held constant, lower annual incidence could 160 compound over time to reduce the prevalence and societal burden of Alzheimer Disease. 161

162

Our findings for saturated fat, trans-fat, and dietary cholesterol are also supported by the literature^{2,24–} 163 ²⁷, but the patterns were not significant in our longitudinal analyses. This is not surprising given the 164 small magnitude of the longitudinal changes in lipid intakes that were observed within countries. 165 Individual level studies, both cross-sectional and longitudinal, generally share the same limitation (i.e. 166 small range of exposure). The results from our free-knot penalized spline regression models remain 167 critical for future research as they indicate that nonlinear relationships should be considered in future 168 inquiries of these lipids. If the relationships reported here are validated in subsequent work, then 169 reductions in saturated fat, trans-fat, and dietary cholesterol may further reduce country-level ASAIR. 170 For countries below the saturated fat threshold of 10% of total daily energy intake, a two standard 171 deviation decrease in saturated fat intake would correspond to a reduction in ASAIR by 24.0 new 172

cases of Alzheimer Disease per 100.000 per vear (2.67*9.0). Similar calculations for trans-fat 173 (7.35*1.4) and dietary cholesterol (0.15*110) would predict 10.3 and 16.5 fewer new cases per 174 100,000 per year, respectively. In 2019 the US had a mean saturated fat intake of 11.8% of total 175 176 daily energy intake, a mean trans-fat intake of 2.8% of total daily energy intake, and a mean dietary cholesterol of 296 mg/day. A two standard deviation decrease for each of these fats would lower the 177 US mean intakes below the identified intake thresholds (10% of total daily energy intake for saturated 178 fat, 1.5% of total daily energy intake for trans-fat, and 250 mg/day for dietary cholesterol). Such a 179 decrease would result in 19.2 fewer new Alzheimer Disease cases per 100,000 per year for saturated 180 fat reductions (2.67*7.2), 0.7 fewer new cases per 100.000 per year for trans-fat reductions 181 (7.35*0.1), and 9.6 fewer new cases per 100,000 per year for dietary cholesterol reductions (0.15*64). 182 When added to the Omega6 PUFA findings, a two standard deviation decrease in Omega6. 183 Saturated fat, trans-fat, and dietary cholesterol could potentially yield a net reduction of 38.7 new 184 cases per 100,000 per year in the US. This would amount to a 35.2% reduction in new cases of 185 Alzheimer Disease in the US each year. ([110-38.7]/110 = 64.8%). In absolute numbers this 186 translates into ~129,645 fewer new cases each year in the US (38.7*[335,000,000/100,000]). Again, 187 the saturated fat, trans-fat, and dietary cholesterol findings still need to be corroborated on the 188 country level, but there is substantial motivation to conduct follow-up studies because of the size of 189 the putative benefits. 190

191

There are limitations to our work. First, we note that our country-level analyses depend on the accurate estimation of mean lipid intakes and ASAIR. These estimates come from peer reviewed publications and extensive care was made to account for potential biases. Second, we note that we had limited covariates available for confounding adjustment and this is a common issue in countrylevel analyses. Nevertheless, we emphasize that the findings in the longitudinal analyses intrinsically account for confounding factors that are stable in time. In other words, confounding by genetic and

environmental factors that are stable within the time course of the analysis, are controlled for by study 198 design. Additionally, we adjusted both our cross-sectional and longitudinal analyses for country 199 development level. This can reduce residual bias from factors that are correlated with country level 200 economic improvement. Perhaps most importantly, the Omega6 PUFA results were validated in the 201 longitudinal models despite limited power (and the other findings revealed supportive trends). A third 202 limitation is that the time lags do not perfectly align between the discovery and validation analyses. 203 We would have preferred to have access to changes in ASAIR between 1999 and 2019 instead of 204 1990 to 2019. However, this is a minor point and the expected random error would likely bias toward 205 the null. Finally, we note that while these findings are very useful for country-level inference and 206 intervention, they are not directly applicable to individual level inference (the ecological fallacy). 207 Therefore, although our results are compelling at the country level, the individual level will require 208 additional study. 209

210

Overall, these findings may provide an approach for reducing ASAIR through food system 211 interventions. If trials confirm our findings, then we can hone the prevention strategies that 212 governments need as populations around the globe get older.²⁸ Importantly, this work stands on vast 213 convergent evidence²⁹ implicating lipid dysfunction in Alzheimer disease etiology.^{1–9} It is now 214 becoming clear that lipid abnormalities are causal factors³⁰ in Alzheimer disease development, and 215 though lipids have not always been the center of focus for Alzheimer researchers, the genetics have 216 been consistently pointing in this direction for over 30 years.^{1,7} Perhaps most importantly, if achieved, 217 diet-based interventions could have large impact on Alzheimer disease incidence. While determining 218 safe, optimal changes to country level lipid intakes needs some additional study, the benefits might 219 extend beyond ASAIR, as excess Omega6 PUFA in our food systems is linked to many other serious 220 and common chronic diseases.^{31,32} The potential ASAIR benefits will vary by country, but based on 221 our estimates for the US, a moderate decrease in Omega6 PUFA intake could reduce ASAIR by 8%. 222

Additional decreases in saturated fat, trans-fat, and dietary cholesterol might yield total ASAIR reductions of 35%. Our findings are promising as they indicate a rather straightforward path to reducing AD burden.

- 226
- 227
- 228
- 229 Online Methods
- 230

Previously published reports were used to obtain mean intake for 5 lipids (Omega6 polyunsaturated 231 fatty acids (Omega6 PUFA), Long Chain Omega3 polyunsaturated fatty acids (Omega3 PUFA), 232 Saturated fat, Trans-fat, and Dietary Cholesterol)^{12,13} and ASAIR¹⁵ for 184 countries. One country, 233 the Maldives, was eliminated from the analyses as it was an extreme outlier with respect to Omega3 234 PUFA (>9 standard deviations above the global mean). The lipid estimates were produced by the 235 Nutrition and Chronic Diseases Expert Group (NutriCoDE) for the 2010 Global Burden of Diseases, 236 Injuries, and Risk Factors Study, and they used a Bayesian hierarchical imputation model to 237 harmonize these estimates from diverse source data^{12,13,33}. ASAIR estimates were produced by the 238 GBD Disease and Injury Incidence and Prevalence Collaborators and downloaded from the IHME 239 Global Health Data Exchange (http://ghdx.healthdata.org/gbd-results-tool) on March 20, 2020¹⁵ 240 Incidence rates in this study are for Alzheimer disease and other dementias (national autopsy 241 programs are not available for diagnostic confirmation at scale). Age standardization was conducted 242 to account for country-level differences in population age distributions and age of dementia onset. 243 Lipid intake data was from 2010 and ASAIR values were from 2019. This 9-year time-lag aligns with 244 optimal lags estimated for environmental factors in Alzheimer Disease epidemiology.³⁴ Omega3 245 PUFA estimates were adjusted to account for endogenous conversion as previously described³⁵. 246 247

248 Cross-sectional Analyses with a Lag

To assess the shape of the 5 lipid-ASAIR relationships, we implemented free-knot penalized 249 regression splines using MGCV in R.¹⁴ The three lipid intakes that demonstrated non-linear 250 relationships with ASAIR in these bivariate regression spline models were specified in the subsequent 251 multivariable-adjusted model with spline terms. Limited covariate data was available for confounding 252 adjustments, but this model was adjusted for all other lipids and country development level based on 253 per capita Gross National Income (GNI)³⁶. The per capita GNI for each country in 2010 was 254 calculated using the World Bank Atlas method as described in Blencowe et al 2012³⁶ (0=Low-income 255 economies, 1=Lower-middle-income, 2=Upper-middle-income and 3=High-income economies). 256 Since the three nonlinear relationships appeared to be linear on either side of a threshold in the 257 bivariate spline models, we also used the thresholds to create 2 strata for each of these lipids (strata 258 within which the lipid-ASAIR relationship appears linear). We then specified linear terms for these 259 lipids and reran the multivariable-adjusted regression model in the two strata separately (to obtain ßs 260 for the linear regions of the lipid-ASAIR relationship). 261

262

263 Longitudinal Analyses

Finally, we compared the percent change in lipid intakes from 1990 to 2010^{12,13} to the percent change 264 in ASAIR between 1990 and 2019¹⁵ with linear regression. We first assessed unadjusted linear 265 regression models within the linear regions of the relationship identified in the analyses described 266 above. Any lipid that yielded significant findings was then evaluated in a multivariable-adjusted model 267 that was adjusted for all other lipids. To identify distinct associations on opposite sides of the 268 thresholds for saturated fat, trans-fat, and dietary cholesterol, we tested for interaction with a 269 dichotomous dummy variable for change-occurred-above-or-below threshold. Finally, we adjusted for 270 changes in country development level based on per capita GNI. This variable was coded as the 271 development level change from 1990 to 2010. Development levels were not available for 27 272

- countries in 1990, but we were able to obtain substitute baseline values for 24 of these countries by 273 using development estimates from 1991 or 1992.³⁷ Thus, only Montenegro, Serbia, and Timor-Leste 274 were excluded due to missing baseline development data in any of these years. Note that the lipid 275 intake information is the percent change in the country-level intake between 1990 and 2010, and the 276 incidence data is percent change in the annual age standardized incidence between 1990 and 2019. 277 Since these units differ from the prior analyses, these data can be used to corroborate association 278 directions, but the association magnitudes are not directly comparable. Descriptive statistics were 279 obtained using SAS 9.4 (Cary, NC) and all other analyses were conducted with R 4.2.1. 280
- 281
- 282

283 **References**

- 284
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993;261(5123):921-923. doi:10.1126/science.8346443
- 2. Honda T, Ohara T, Shinohara M, et al. Serum elaidic acid concentration and risk of dementia: The Hisayama Study. *Neurology*. 2019;93(22):e2053-e2064. doi:10.1212/WNL.000000000008464
- Abdullah L, Evans JE, Emmerich T, et al. APOE ε4 specific imbalance of arachidonic acid and
 docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive
 Impairment/Alzheimer's Disease. *Aging*. 2017;9(3):964-985. doi:10.18632/aging.101203
- Ebright B, Assante I, Poblete RA, et al. Eicosanoid lipidome activation in post-mortem brain
 tissues of individuals with APOE4 and Alzheimer's dementia. *Alzheimers Res Ther*.
 2022;14(1):152. doi:10.1186/s13195-022-01084-7
- Moulton MJ, Barish S, Ralhan I, et al. Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer's disease-associated genes. *Proc Natl Acad Sci U S A*. 2021;118(52). doi:10.1073/pnas.2112095118
- Thomas MH, Paris C, Magnien M, et al. Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA(2) balance. *Alzheimers Res Ther*. 2017;9(1):69. doi:10.1186/s13195-017-0295-1
- Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's
 disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat Genet*.
 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2
- Chew H, Solomon VA, Fonteh AN. Involvement of Lipids in Alzheimer's Disease Pathology and
 Potential Therapies. *Front Physiol*. 2020;11:598. doi:10.3389/fphys.2020.00598
- Haney MS, Pálovics R, Munson CN, et al. APOE4/4 is linked to damaging lipid droplets in
 Alzheimer's disease microglia. *Nature*. Published online March 13, 2024. doi:10.1038/s41586 024-07185-7
- 10. Nwaru BI, Dierkes J, Ramel A, et al. Quality of dietary fat and risk of Alzheimer's disease and
 dementia in adults aged ≥50 years: a systematic review. *Food Nutr Res.* 2022;66.
 doi:10.29219/fnr.v66.8629
- 11. Pearce N. The ecological fallacy strikes back. *J Epidemiol Community Health*. 2000;54(5):326 327.
- Micha R, Khatibzadeh S, Shi P, et al. Global, regional, and national consumption levels of dietary
 fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition
 surveys. *BMJ*. 2014;348:g2272. doi:10.1136/bmj.g2272

- 318 13. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a
 319 systematic analysis including 266 country-specific nutrition surveys. *BMJ*. 2015;350:h1702.
 320 doi:10.1136/bmj.h1702
- 14. Wood SN. Package 'mgcv': GAMs with GCV/AIC/REML smoothness estimation and GAMMs by
 PQL. Published November 30, 2010. Accessed November 30, 2010. https://cran.r-
- project.org/web/packages/mgcv/mgcv.pdf accessed 11/30/2010
- 15. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer's
 disease and other dementias, 1990-2019. *Front Aging Neurosci*. 2022;14:937486.
 doi:10.3389/fnagi.2022.937486
- 16. Hammouda S, Ghzaiel I, Khamlaoui W, et al. Genetic variants in FADS1 and ELOVL2 increase
 level of arachidonic acid and the risk of Alzheimer's disease in the Tunisian population.
 Prostaglandins Leukot Essent Fatty Acids. 2020;160:102159. doi:10.1016/j.plefa.2020.102159
- 17. Sanchez-Mejia RO, Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease.
 Biochim Biophys Acta. 2010;1801(8):784-790. doi:10.1016/j.bbalip.2010.05.013
- 18. Sanchez-Mejia RO, Newman JW, Toh S, et al. Phospholipase A2 reduction ameliorates cognitive
 deficits in a mouse model of Alzheimer's disease. *Nat Neurosci*. 2008;11(11):1311-1318.
 doi:10.1038/nn.2213
- 19. Thomas MH, Pelleieux S, Vitale N, Olivier JL. Dietary arachidonic acid as a risk factor for age associated neurodegenerative diseases: Potential mechanisms. *Biochimie*. 2016;130:168-177.
 doi:10.1016/j.biochi.2016.07.013
- 20. Goozee K, Chatterjee P, James I, et al. Alterations in erythrocyte fatty acid composition in
 preclinical Alzheimer's disease. *Sci Rep.* 2017;7(1):676. doi:10.1038/s41598-017-00751-2
- 21. Hosseini M, Poljak A, Braidy N, Crawford J, Sachdev P. Blood fatty acids in Alzheimer's disease
 and mild cognitive impairment: A meta-analysis and systematic review. *Ageing Res Rev.* 2020;60:101043. doi:10.1016/j.arr.2020.101043
- 22. Zhang JY, Kothapalli KS, Brenna JT. Desaturase and elongase-limiting endogenous long-chain
 polyunsaturated fatty acid biosynthesis. *Curr Opin Clin Nutr Metab Care*. 2016;19(2):103-110.
 doi:10.1097/mco.000000000254
- 23. Peña-Bautista C, Álvarez-Sánchez L, Cañada-Martínez AJ, Baquero M, Cháfer-Pericás C.
 Epigenomics and Lipidomics Integration in Alzheimer Disease: Pathways Involved in Early
 Stages. *Biomedicines*. 2021;9(12). doi:10.3390/biomedicines9121812
- 24. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk
 of incident dementia in the Rotterdam Study. *Ann Neurol.* 1997;42(5):776-782.
 doi:10.1002/ana.410420514
- 25. Grant WB, Blake SM. Diet's Role in Modifying Risk of Alzheimer's Disease: History and Present
 Understanding. *J Alzheimers Dis JAD*. 2023;96(4):1353-1382. doi:10.3233/JAD-230418

- Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased
 risk of Alzheimer's and vascular dementia three decades later. *Dement Geriatr Cogn Disord*.
 2009;28(1):75-80. doi:10.1159/000231980
- Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Dietary fat intake and 6-year
 cognitive change in an older biracial community population. *Neurology*. 2004;62(9):1573-1579.
 doi:10.1212/01.wnl.0000123250.82849.b6
- 28. Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating
 evidence into policy. *Lancet Neurol.* 2020;19(3):255-265. doi:10.1016/S1474-4422(19)30411-9
- 29. Ciesielski TH, Pendergrass SA, White MJ, et al. Diverse convergent evidence in the genetic
 analysis of complex disease: coordinating omic, informatic, and experimental evidence to better
 identify and validate risk factors. *BioData Min*. 2014;7:10. doi:10.1186/1756-0381-7-10
- 365 30. Rothman KJ. Causes. *Am J Epidemiol*. 1976;104(6):587-592.
- doi:10.1093/oxfordjournals.aje.a112335
- 367 31. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary
 368 omega-6 polyunsaturated Fatty acids. *J Nutr Metab.* 2012;2012:539426.
 369 doi:10.1155/2012/539426
- 370 32. Mariamenatu AH, Abdu EM. Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAs)
 versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their
 "Balanced Antagonistic Metabolic Functions" in the Human Body. *J Lipids*. 2021;2021:8848161.
 doi:10.1155/2021/8848161
- 374 33. Micha R, Kalantarian S, Wirojratana P, et al. Estimating the global and regional burden of
 suboptimal nutrition on chronic disease: methods and inputs to the analysis. *Eur J Clin Nutr.* 2012;66(1):119-129. doi:10.1038/ejcn.2011.147
- 377 34. Mork D, Braun D, Zanobetti A. Time-lagged relationships between a decade of air pollution
 ary exposure and first hospitalization with Alzheimer's disease and related dementias. *Environ Int.* 2023;171:107694. doi:10.1016/j.envint.2022.107694
- 380 35. Ciesielski TH, Williams SM. Low Omega-3 intake is associated with high rates of depression and 381 preterm birth on the country level. *Sci Rep.* 2020;10(1):19749. doi:10.1038/s41598-020-76552-x
- 382 36. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of
 383 preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a
 384 systematic analysis and implications. *Lancet*. 2012;379(9832):2162-2172. doi:10.1016/s0140385 6736(12)60820-4
- 37. Hamadehc N, Van Rompaey C, Metrea E. World Bank Group country classifications by income
 level. Accessed March 12, 2024. https://blogs.worldbank.org/opendata/new-world-bank-group country-classifications-income-level-fy24
- 389

391 Acknowledgements

- 392 The authors would like to thank the many people who contributed to the country-level estimates that
- 393 were used in these analyses.
- 394
- 395 **Conflicts**
- 396 None
- 397

398 **Funding Sources**

- RD was supported by a National Institutes of Health F grant (F30AG082434). The other authors were
- supported by the National Institute on Aging (U19 AG074865), which was awarded to GT, FR, ROA,
- 401 GSB, WSB, BWK, CR, JMV, MPV, JLH, and SMW. The funding source had no role in the collection,
- analysis, interpretation of data, writing of the report, or submission decision.
- 403

404 **Consent statement**

- 405 NA This analysis used country-level data from previously published papers.
- 406

407 Key Words

- Alzheimer's disease, dementia, lipids, epidemiology, prevention, diet, population health
- 409
- 410
- 411
- 412
- 413

414 **Table 1: Descriptive statistics for the 183 countries**

415

	Mean	Standard Deviation	Median	25th Percentile	75th Percentile	Min	Max
Outcome Variable							
Age Standardized Alzheimer							
Disease Incidence (ASAIR) ^a	91.6	11.7	90.0	80.0	100.0	60.0	110.0
(new cases annually per 100,000)							
Exposure Variables							
Omega 6 PUFA ^b	E 1	1.0	10	2 7	6.2	1 2	12 5
(% of total daily energy intake)	5.1	1.9	4.9	5.7	0.5	1.2	12.5
Long Chain Omega3 PUFA ^b	272	272	261	152	403	25	2011
(mg/day)	525	273	201	155	403	35	2011
Saturated Fat ^b	11.6	4 5	11.0	0 0	12 7	22	27 E
(% of total daily energy intake)	11.0	4.5	11.0	0.0	13.7	2.5	27.5
Trans-fat ^b	1.1	0.7	1.0	0.8	1.2	0.2	6.5
(% of total daily energy intake)							
Dietary Cholesterol ^b	249	55	247	209	286	97	439
(mg/day)							
Gross National Income ^c	1.6	1.1	2	1	3	0	3

^a ASAIR estimates were obtained from Li et al 2022.¹⁵ They were produced by the *GBD Disease and Injury Incidence and Prevalence Collaborators* and downloaded from the IHME Global Health Data Exchange
 (http://ghdx.healthdata.org/gbd-results-tool) on March 20, 2020.

^b Lipid estimates were obtained from Micha et al 2015.^{12,13,33} They were produced by the *Nutrition and*

Chronic Diseases Expert Group (NutriCoDE) for the 2010 Global Burden of Diseases, Injuries, and Risk Factors
 Study, and they used a Bayesian hierarchical imputation model harmonize theses estimates from diverse
 source data^{12,13,33}.

^c The development level (based on per capita GNI) for each country in 2010 was calculated using the World
 Bank Atlas method as described in Blencowe et al 2012³⁶ (0=Low-income economies, 1=Lower-middle-income,

425 2=Upper-middle-income and 3=High-income economies)

426

427

428

429

430

432 Table 2: Results from regression models of age standardized Alzheimer Disease incidence on

433 the country-level

434

	Change in Age Standardized Alzheimer Disease Incidence associated with a 1 unit increase in country-level lipid (β)	95% CI	p value
Omega6 PUFA (% of energy intake) ^a	2.44	1.70, 3.19	1.38x10 ⁻⁹
Long Chain Omega3 PUFA (mg/day) ^a	-0.004	-0.010, 0.001	1.11x10 ⁻¹
Gross National Income ^a	0.29	-1.34 1.92	7.28x10 ⁻¹
Saturated Fat (% of energy intake) ^b			
Below the threshold of 10	2.67	1.23, 4.11	5.71x10 ⁻⁴
Above the threshold of 10	0.04	-0.44, 0.53	8.62x10 ⁻¹
Trans-fat (% of energy intake) °			
Below the threshold of 1.5	7.35	0.79, 13.90	2.96x10 ⁻²
Above the threshold of 1.5	0.70	-1.89, 3.29	6.03x10 ⁻¹
Dietary Cholesterol (mg/day) ^d			
Below the threshold of 250	0.15	0.07, 0.23	5.98x10 ⁻⁴
Above the threshold of 250	0.02	-0.03, 0.07	3.61x10 ⁻¹

435

a Multivariable model with Omega6 PUFA, Long Chain Omega3 PUFA (mg/day) and Gross National Income
 modeled with linear terms, and Saturated Fat, Dietary Cholesterol, and Trans-fat were modeled with penalized
 splines.

b The same model as in a, but now with a linear term for Saturated Fat, and evaluated in two separate strata

(above and below the threshold of 10% Saturated fat by total energy intake)

c The same model as in a, but now with a linear term for Trans-fat, and evaluated in two separate strata

442 (above and below the threshold of 1.5% Trans-fat by total energy intake)

d The same model as in a, but now with a linear term for Dietary Cholesterol, and evaluated in two separate
 strata (above and below the threshold of 250 mg/day of Dietary Cholesterol)

- 445
- 446
- 447
- 448

Table 3: Longitudinal changes in lipid intakes and age standardized Alzheimer Disease incidence in the 183 countries

451

	Mean	Standard Deviation	Median	25th Percentile	75th Percentile	Min	Max
Outcome Variable							
Percent Change in Annual Age							
Standardized Alzheimer Disease	0.012	0.111	0.020	-0.040	0.070	-0.420	0.580
Incidence from 1990 to 2019 ^a							
Exposure Variables							
Percent Change in Omega 6 PUFA from 1990 to 2010 ^b	0.42	0.83	0.30	-0.10	0.70	-2.00	3.40
Percent Change in Long Chain Omega3 PUFA from 1990 to 2010 ^b	58	79	41	9	94	-193	400
Percent Change in Saturated Fat from 1990 to 2010 ^b	0.05	1.32	0.00	-0.60	0.50	-4.40	4.60
Percent Change in Trans-fat from 1990 to 2010 ^b	0.07	0.21	0.00	0.00	0.10	-0.80	1.50
Percent Change in Dietary Cholesterol from 1990 to 2010 ^b	3.6	19.9	2.2	-10.3	15.7	-57.0	57.8
Change in Gross National Income from 1990 to 2010 ^c	0.38	0.60	0	0	1	-1	2

452

^a ASAIR estimates were obtained from Li et al 2022.¹⁵ They were produced by the *GBD Disease and Injury Incidence and Prevalence Collaborators* and downloaded from the IHME Global Health Data Exchange
 (http://ghdx.healthdata.org/gbd-results-tool) on March 20, 2020.

^b Lipid estimates were obtained from Micha et al 2015.^{12,13,33} They were produced by the *Nutrition and*

Chronic Diseases Expert Group (NutriCoDE) for the 2010 Global Burden of Diseases, Injuries, and Risk Factors
 Study, and they used a Bayesian hierarchical imputation model harmonize theses estimates from diverse
 source data^{12,13,33}.

^c This variable was coded as the country development level change (based on per capita GNI) from 1990 to

461 2010. Development levels were not available for 27 countries in 1990, but we were able to obtain substitute

462 country development baseline values for 24 of these countries by using an estimate from 1991 or 1992.³⁷

463 Thus, only Montenegro, Serbia, and Timor-Leste were missing country development level change data.

Table 4: Results from linear regression models of percent change in annual age standardized 465 Alzheimer Disease Incidence from 1990 to 2019 466

467

	Percent Change in Annual Age Standardized Alzheimer Disease Incidence from 1990 to 2019 associated with a 1% increase in country-level lipid intake (β)	95% CI	p value
Unadjusted Models			
Percent Change in Omega 6 PUFA from 1990 to 2010	3.41x10 ⁻⁰²	1.54x10 ⁻⁰² , 5.29x10 ⁻⁰²	4.70x10 ⁻⁰⁴
Percent Change in Long Chain Omega3 PUFA from 1990 to 2010	9.63x10 ⁻⁵	-1.08x10 ⁻⁴ , 3.01x10 ⁻⁴	3.58x10 ⁻¹
Percent Change in Saturated Fat from 1990 to 2010			
Below the threshold of 10	4.38 x10 ⁻³	-1.83x10 ⁻² , 2.70x10 ⁻²	7.06x10 ⁻¹
Above the threshold of 10	-2.39x10 ⁻³	-1.71x10 ⁻² , 1.23x10 ⁻²	7.51x10 ⁻¹
Percent Change in Trans-fat from 1990 to 2010			
Below the threshold of 1.5	1.37x10 ⁻¹	-2.43x10 ⁻² , 2.98x10 ⁻¹	9.82 x10 ⁻²
Above the threshold of 1.5	2.28x10 ⁻²	-6.33x10 ⁻² , 1.09x10 ⁻¹	6.08 x10 ⁻¹
Percent Change in Dietary Cholesterol			
Below the threshold of 250	9.23 ×10 ⁻⁴	-2.44 x10 ⁻⁴ , 2.09 x10 ⁻³	1.24 x10 ⁻¹
Above the threshold of 250	2.14 x10 ⁻⁵	-1.16 x10 ⁻³ , 1.20 x10 ⁻³	9.72 x10 ⁻¹
Multivariable Adjusted Model ^a			
Percent Change in Omega 6 PUFA from 1990 to 2010	3.75x10 ⁻⁰²	1.64x10 ⁻⁰² , 5.86x10 ⁻⁰²	6.50x10 ⁻⁰⁴

^a Adiusted for: Percent Change in Long Chain Omega3 PUFA, Percent Change in Saturated Fat, Percent Change 468 in Trans-fat, and Percent Change in Dietary Cholesterol, and change in Gross National Income level. To 469

account for distinct associations on opposite sides of the threshold for saturated fat, the saturated fat variable 470

was interacted with a dichotomous dummy variable for *change-occurred-above-or-below threshold*. Trans-fat 471 and dietary cholesterol also had thresholds and were modeled in the same way. 472

Figure 1. Free-knot penalized splines showing the relationship between country-level lipid intakes and age standardized incidence of Alzheimer Disease and other dementias

Incidence is on the y-axis and the y axis range is the same for all 5 plots, for ease of comparison. Each plot depicts the penalized
regression spline for a distinct class of country-level lipid data: (A) Omega6 PUFA (B) Long Chain Omega3 PUFA (C) Saturated Fat
(D) Trans-fat and (E) Dietary Cholesterol intake. The dashed lines depict 95% CIs and the hash marks along the x-axis depict data
density. Estimates are imprecise in regions of low data density. Nonlinear relationships were detected by the GCV process for
Saturated Fat, Trans-fat, Dietary Cholesterol (panels C-E). Apparent thresholds are indicated with a vertical red line.



Research in Context

<u>Evidence before this study</u>: Convergent evidence from genetics, neuropathology, laboratory experiments, and epidemiology indicates that lipids play a central role in the development of Alzheimer Disease (AD). However, the relative importance of different lipids remains unclear, and individual-level epidemiologic studies are often not well suited to address this question. Large cohort studies rarely have precise dietary information on specific lipid intakes over decades, and even where these data are available, the lipid intakes among individuals do not typically vary enough within a study population to discern patterns of association. Additionally, multiple categories of lipids are not usually available in one dataset, so their relative associations cannot be compared. Lastly, the potential for nonlinear relationships is rarely considered. These caveats often lead to equivocal conclusions upon meta-analysis. However, each of these issues is addressable with analyses on the country-level.

<u>Added value of this study</u>: Here we obtained country-level data on five lipid intakes, and compared them to age-standardized Alzheimer Disease Incidence rates (ASAIR) using free-knot penalized spline regression and linear regression. We found that Omega6 Polyunsaturated-Fatty-Acid (PUFA) intake exhibited a linear and significant relationship with ASAIR and it was validated in a follow-up longitudinal analysis. Additionally, we found non-linear relationships between saturated-fat, transfat, dietary-cholesterol and ASAIR. For each of these, ASAIR increased with lipid intake up to a threshold although these relationships were not statistically significant in the longitudinal analysis.

<u>Implications of all the available evidence</u>: When combined with the pre-existing evidence, these analyses indicate that decreasing Omega6-PUFA consumption on the country-level may have substantial benefits in reducing AD rates. Further research is needed on all these lipids, but country level reductions in saturated-fat, trans-fat, dietary-cholesterol intake, hold similar promise for reducing the country level burden of dementia. When considered in aggregate, reductions in the mean intake of four lipids may yield significant reductions in AD incidence. Individual level studies must be conducted to determine the impact of lipid intakes on specific people.

Highlights

Diverse convergent evidence indicates that lipids play a role in Alzheimer Disease.

Individual-level studies are often not well suited to study lipid consumption.

Incidence of Alzheimer Disease and other dementias increased with mean country-level Omega6 PUFA intake

It also increased with saturated-fat, trans-fat, and cholesterol up to a threshold.

The country-level Omega6 PUFA finding was validated in longitudinal analyses.